Journal
UROLOGIC CLINICS OF NORTH AMERICA
Volume 47, Issue 3, Pages 329-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ucl.2020.04.010
Keywords
Neoadjuvant therapy; Targeted therapy; Immune checkpoint inhibitor; Renal cell carcinoma; Locally advanced; Nephrectomy; Partial nephrectomy
Categories
Ask authors/readers for more resources
There has been strong interest in using neoadjuvant therapy to decrease recurrence rates and facilitate surgical resection in locally advanced renal cell carcinoma. To date, no evidence exists to support improvement in oncologic outcomes with neoadjuvant therapy. Likewise, although targeted therapies have shown efficacy in tumor downsizing, this does not often translate to downstaging. Use of presurgical therapy for the purpose of downstaging inferior vena cava tumor thrombi is currently not supported. Future studies evaluating the benefit of newer immune checkpoint inhibitors will determine if there is a larger role for neoadjuvant therapy in locally advanced renal cell carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available